Shares in Caliper Life Sciences fell nearly 10 percent for the five-day trading period ended Tuesday, despite the firm’s announcement last week that it had received a key patent allowance (see related article). The firm also reaffirmed its full-year revenue guidance of $137 million to $143 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.